The FDA has approved the expansion of Trikafta to include 94 additional rare CFTR mutations, giving more people with cystic fibrosis (CF) access to a treatment that targets the underlying cause of their disease. This milestone means that individuals who were previously ineligible for CFTR modulators may now benefit from this groundbreaking therapy.
